On March 3, 2020, Inovio publicized “an accelerated timeline for developing its DNA vaccine INO-4800.” The Company’s CEO said that, “[u]sing our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19.”
The complaint alleges that defendants misled investors regarding the feasibility of its Covid-19 vaccine, just three hours after publication of the Covid-19 DNA sequence.
Inovio Pharmaceuticals, Inc.
Investors who purchased the Company’s securities between February 14, 2020 and March 9, 2020 are encouraged to contact the firm prior to May 12, 2020.
If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
8240 Beverly Blvd., Suite 9
Los Angeles, CA 90048
info@portnoylaw.com
